Germany: Fresenius succeeds with new euro benchmark

Following last week’s US$1bn 10-year paper from subsidiary Fresenius Medical Care, parent Fresenius decided to remain in the euro market with its own two-part €1bn (US$1.2bn) deal. It sold €500m six-year paper at 0.375%. The September 2026s priced at 99.333% to yield 0.488%. It also sold €500m January 2033s at 1.125%. They priced at 99.738%…

You must be a HMI Subscriber to view this content.

Subscribe Now »